Superworth

Coherus Oncology price to sales ratio CHRS

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026
3.1×
10-year median
2.5×
Against its 10-year history
70th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.3× to 28.4×
Peer median
2.2×

Coherus Oncology's price to sales ratio is 3.1× as of Oct 23, 2026.

That is above its ten-year median of 2.5×, higher than on 70% of days in the last ten years.

Over that time it ranged from 0.3× in Nov 2024 to 28.4× in Oct 2016.

The median for 10 healthcare stocks of a similar size is 2.2×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.1×2.0×7.0×
20251.9×0.3×2.0×
20240.6×0.3×1.5×
20231.8×0.8×3.4×
20222.6×1.6×3.9×
20213.4×2.1×3.9×
20202.6×2.4×6.8×
20195.5×5.4×5.7×
2018n/m a value too high to mean anything
20173.4×3.4×27.8×
201628.1×16.3×31.2×
201541.2×22.6×44.4×

Against its peers

Companies in Healthcare nearest Coherus Oncology's size, closest first, today.

CompanyPrice to sales ratio
CHRSCoherus Oncology3.1×
PDEXPro DEX2.6×
PLXProtalix BioTherapeutics2.5×
NATRNatures Sunshine Products0.4×
ELMDElectromed3.0×
UTMDUtah Medical Products6.5×
KEQUKewaunee Scientific0.3×
ICCCImmucell3.0×
INFUInfuSystem1.9×
LFVNLifevantage0.4×
VMDViemed Healthcare1.2×
Peer median2.2×

Where Coherus Oncology ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Coherus Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.